<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01618695</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-J000-335</org_study_id>
    <nct_id>NCT01618695</nct_id>
  </id_info>
  <brief_title>A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy and safety of perampanel compared to
      placebo in patients with refractory partial-onset seizures
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2012</start_date>
  <completion_date type="Actual">May 28, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)</measure>
    <time_frame>Baseline, Week 19</time_frame>
    <description>Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. All partial seizure included simple partial seizures without motor signs, simple partial with motor signs, complex partial, and complex partial with secondary generalized seizures. A simple partial seizure takes place on one side of the brain. Usually, people experiencing a simple partial seizure do not lose consciousness or awareness. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain. The seizure affects people's awareness and may cause them to lose consciousness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Baseline, Week 19</time_frame>
    <description>Responder rate was percentage of participants with greater than or equal to (&gt;=) 50% reduction in seizure frequency during maintenance period of the randomization phase relative to prerandomization phase (baseline). If the reduction in seizure frequency is less than (&lt;) 50%, then the participants are considered as non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline)</measure>
    <time_frame>Baseline, Week 19</time_frame>
    <description>Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain and it affects awareness and may cause in loss of consciousness. Secondary generalized seizures begin in one part of the brain, but then spread to both sides of the brain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores</measure>
    <time_frame>Baseline, Week 19</time_frame>
    <description>The investigator evaluated each participant for CGIC questionnaire to assess change in participant's disease clinical status from baseline. Assessment evaluated frequency of seizures, severity of seizures, occurrence of adverse events, and overall functional status of the participant using the 7-point scale. The evaluation used a 7-point scale with the scores 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Lower score indicated improvement. Higher score indicated worsening.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">940</enrollment>
  <condition>Partial-onset Seizures</condition>
  <arm_group>
    <arm_group_label>Perampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.
Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day.</description>
    <arm_group_label>Perampanel</arm_group_label>
    <other_name>E2007</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Core study: Week 0 to Week 18 Once daily placebo.
Extension study:
Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male or female and greater than or equal to 12 years of age;

          2. Have a diagnosis of epilepsy with partial seizures with or without secondarily
             generalized seizures

          3. Participants with computed tomography (CT) or magnetic resonance imaging (MRI)
             diagnosis within the last 10 years (for adults) and 5 years (for adolescents) prior to
             visit 1 that ruled out progressive central nervous system (CNS) disorders, example,
             neurodegenerative disorders, brain tumors. For participants without existing CT or MRI
             results, CT or MRI was performed at or after Visit 1 but results evaluation was
             performed by Visit 2

          4. Participants who had been treated for at least 12 weeks but confirmed to be
             uncontrolled with more than one standard antiepileptic drug (AED) for 2 years before
             enrollment

          5. During the 6-week Prerandomization Phase participants must have had greater than or
             equal to 5 partial seizures per 6-week

          6. Are currently being treated with stable doses and administrations of 1, 2, or a
             maximum of 3 approved AEDs. Only 1 inducer AED (defined as carbamazepine, phenytoin or
             oxcarbazepine only) out of the maximum of 3 AEDs is allowed

        Exclusion Criteria

          1. Presence of nonmotor simple partial seizures only;

          2. Presence of primary generalized epilepsies or seizures, such as absences and/or
             myoclonic epilepsies;

          3. Presence or previous history of Lennox-Gastaut syndrome;

          4. A history of status epilepticus within 1 year prior to screening

          5. Seizure clusters where individual seizures cannot be counted

          6. A history of psychogenic seizures within 5 years prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #3</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #3</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #3</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>T≈çon</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Koga</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Itami</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Zentsuji</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Goshi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Tamana</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Iwanuma</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Miyakonojo</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Izumi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Asaka</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Higashimurayama</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Moriyama</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Matsue</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Komatsushima</city>
        <state>Tokushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kokubunji</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #3</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #4</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #5</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #6</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #7</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #8</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Perak</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Terengganu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Rajathevee</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #1</name>
      <address>
        <city>Tha Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #2</name>
      <address>
        <city>Tha Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #3</name>
      <address>
        <city>Tha Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility #4</name>
      <address>
        <city>Tha Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <results_first_submitted>May 20, 2020</results_first_submitted>
  <results_first_submitted_qc>May 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2020</results_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Partial-onset Seizures</keyword>
  <keyword>partial seizures</keyword>
  <keyword>seizure</keyword>
  <keyword>epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 119 investigative sites in Australia, China, Korea, Japan, Malaysia, Taiwan, and Thailand. A total of 940 participants were enrolled and screened, of which 230 were screen failures, 710 were randomized in Core Phase of study.</recruitment_details>
      <pre_assignment_details>This study included a Core Phase and an Extension Phase. This result summary includes data only for the Core Phase of the study at the primary completion date (15 September 2014). Extension Phase results will be provided upon study completion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).</description>
        </group>
        <group group_id="P2">
          <title>Perampanel 4 mg</title>
          <description>Participants received perampanel 2 milligrams (mg) tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Perampanel 8 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Perampanel 12 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="177"/>
                <participants group_id="P4" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated (Safety Analysis Set)</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="175"/>
                <participants group_id="P4" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="147"/>
                <participants group_id="P4" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one post-dose safety assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).</description>
        </group>
        <group group_id="B2">
          <title>Perampanel 4 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Perampanel 8 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Perampanel 12 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="175"/>
            <count group_id="B4" value="180"/>
            <count group_id="B5" value="707"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="13.21"/>
                    <measurement group_id="B2" value="33.1" spread="13.18"/>
                    <measurement group_id="B3" value="33.6" spread="14.11"/>
                    <measurement group_id="B4" value="32.3" spread="12.30"/>
                    <measurement group_id="B5" value="33.4" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="361"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="705"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="667"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)</title>
        <description>Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. All partial seizure included simple partial seizures without motor signs, simple partial with motor signs, complex partial, and complex partial with secondary generalized seizures. A simple partial seizure takes place on one side of the brain. Usually, people experiencing a simple partial seizure do not lose consciousness or awareness. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain. The seizure affects people's awareness and may cause them to lose consciousness.</description>
        <time_frame>Baseline, Week 19</time_frame>
        <population>Intent-to-treat (ITT) Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Perampanel 4 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 8 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 12 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)</title>
          <description>Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. All partial seizure included simple partial seizures without motor signs, simple partial with motor signs, complex partial, and complex partial with secondary generalized seizures. A simple partial seizure takes place on one side of the brain. Usually, people experiencing a simple partial seizure do not lose consciousness or awareness. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain. The seizure affects people's awareness and may cause them to lose consciousness.</description>
          <population>Intent-to-treat (ITT) Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.76" lower_limit="-90.4" upper_limit="400.0"/>
                    <measurement group_id="O2" value="-17.32" lower_limit="-97.1" upper_limit="473.4"/>
                    <measurement group_id="O3" value="-28.95" lower_limit="-100.0" upper_limit="809.4"/>
                    <measurement group_id="O4" value="-38.03" lower_limit="-100.0" upper_limit="456.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2330</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-5.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.112</ci_lower_limit>
            <ci_upper_limit>4.519</ci_upper_limit>
            <estimate_desc>Median Difference to placebo and the 95 percent (%) confidence interval are based on the Hodges-Lehmann method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-16.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.683</ci_lower_limit>
            <ci_upper_limit>-7.251</ci_upper_limit>
            <estimate_desc>Median Difference to placebo and the 95% confidence interval are based on the Hodges-Lehmann method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-24.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.878</ci_lower_limit>
            <ci_upper_limit>-16.235</ci_upper_limit>
            <estimate_desc>Median Difference to placebo and the 95% confidence interval are based on the Hodges-Lehmann method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF)</title>
        <description>Responder rate was percentage of participants with greater than or equal to (&gt;=) 50% reduction in seizure frequency during maintenance period of the randomization phase relative to prerandomization phase (baseline). If the reduction in seizure frequency is less than (&lt;) 50%, then the participants are considered as non-responders.</description>
        <time_frame>Baseline, Week 19</time_frame>
        <population>ITT Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Perampanel 4 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 8 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 12 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF)</title>
          <description>Responder rate was percentage of participants with greater than or equal to (&gt;=) 50% reduction in seizure frequency during maintenance period of the randomization phase relative to prerandomization phase (baseline). If the reduction in seizure frequency is less than (&lt;) 50%, then the participants are considered as non-responders.</description>
          <population>ITT Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="23.0"/>
                    <measurement group_id="O3" value="36.0"/>
                    <measurement group_id="O4" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3954</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline)</title>
        <description>Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain and it affects awareness and may cause in loss of consciousness. Secondary generalized seizures begin in one part of the brain, but then spread to both sides of the brain.</description>
        <time_frame>Baseline, Week 19</time_frame>
        <population>ITT Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data. Here &quot;overall number of participants analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Perampanel 4 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 8 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 12 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline)</title>
          <description>Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain and it affects awareness and may cause in loss of consciousness. Secondary generalized seizures begin in one part of the brain, but then spread to both sides of the brain.</description>
          <population>ITT Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data. Here &quot;overall number of participants analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.70" lower_limit="-88.6" upper_limit="400.0"/>
                    <measurement group_id="O2" value="-19.08" lower_limit="-100.0" upper_limit="410.0"/>
                    <measurement group_id="O3" value="-33.68" lower_limit="-100.0" upper_limit="1103.4"/>
                    <measurement group_id="O4" value="-41.80" lower_limit="-100.0" upper_limit="456.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0552</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-8.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.067</ci_lower_limit>
            <ci_upper_limit>1.671</ci_upper_limit>
            <estimate_desc>Median Difference to placebo and the 95% confidence interval are based on the Hodges-Lehmann method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-21.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.941</ci_lower_limit>
            <ci_upper_limit>-11.368</ci_upper_limit>
            <estimate_desc>Median Difference to placebo and the 95% confidence interval are based on the Hodges-Lehmann method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-28.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.698</ci_lower_limit>
            <ci_upper_limit>-19.794</ci_upper_limit>
            <estimate_desc>Median Difference to placebo and the 95% confidence interval are based on the Hodges-Lehmann method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores</title>
        <description>The investigator evaluated each participant for CGIC questionnaire to assess change in participant's disease clinical status from baseline. Assessment evaluated frequency of seizures, severity of seizures, occurrence of adverse events, and overall functional status of the participant using the 7-point scale. The evaluation used a 7-point scale with the scores 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Lower score indicated improvement. Higher score indicated worsening.</description>
        <time_frame>Baseline, Week 19</time_frame>
        <population>ITT Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Perampanel 4 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Perampanel 8 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Perampanel 12 mg</title>
            <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores</title>
          <description>The investigator evaluated each participant for CGIC questionnaire to assess change in participant's disease clinical status from baseline. Assessment evaluated frequency of seizures, severity of seizures, occurrence of adverse events, and overall functional status of the participant using the 7-point scale. The evaluation used a 7-point scale with the scores 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Lower score indicated improvement. Higher score indicated worsening.</description>
          <population>ITT Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one postdose seizure frequency data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of first dose up to 30 days after the last dose of study drug (up to Week 23)</time_frame>
      <desc>Safety Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and have at least one post-dose safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).</description>
        </group>
        <group group_id="E2">
          <title>Perampanel 4 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Perampanel 8 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Perampanel 12 mg</title>
          <description>Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Partial seizures with secondary generalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Self-injurious ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive granulation tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="155" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dysmetropsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Keratoconjunctivitis sicca</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Normal tension glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gingival hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gingival ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Foreign body reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tooth injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood parathyroid hormone abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood triglycerides abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Weight fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Myokymia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Clumsiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cranial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyslalia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Partial seizures with secondary generalisation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tongue biting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Confusional arousal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Expressive language disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Impatience</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Obsessive-compulsive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Regressive behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Self-injurious ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sleep talking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Soliloquy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Stubbornness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bladder irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cervical cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypomenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pelvic fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pityriasis alba</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Inquiry Service.</name_or_title>
      <organization>Eisai Co., Ltd.</organization>
      <email>eisai-chiken_hotline@hhc.eisai.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

